NBIO (Nascent Biotech) Beginning Cash Position: $0.37 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nascent Biotech Beginning Cash Position?

Nascent Biotech NBIO Beginning Cash Position is $0.37 Mil as of Jun. 2024.

Nascent Biotech's Beginning Cash Position for the quarter that ended in Jun. 2024 was $0.37 Mil.

Nascent Biotech's quarterly Beginning Cash Position declined from Dec. 2023 ($0.95 Mil) to Mar. 2024 ($0.72 Mil) and declined from Mar. 2024 ($0.72 Mil) to Jun. 2024 ($0.37 Mil).

Nascent Biotech's annual Beginning Cash Position increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.09 Mil) and increased from Mar. 2023 ($0.09 Mil) to Mar. 2024 ($0.17 Mil).

Nascent Biotech Beginning Cash Position Related Terms

Nascent Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Beginning Cash Position Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beginning Cash Position
Get a 7-Day Free Trial 0.13 0.00 0.00 0.09 0.17

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 1.35 0.95 0.72 0.37

Nascent Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.37 Mil mean?
Nascent Biotech (NBIO) has a Beginning Cash Position of $0.37 Mil as of Jun. 2024. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Beginning Cash Position too high?
Nascent Biotech's current Beginning Cash Position is $0.37 Mil.
How does Nascent Biotech's Beginning Cash Position compare to BTAX and PXMD?
Nascent Biotech's Beginning Cash Position of $0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current Beginning Cash Position is $0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Beginning Cash Position of $0.37 Mil. The current Beginning Cash Position is $0.37 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Beginning Cash Position is $0.37 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.